INTRODUCTION
Programmed cell death (apoptosis) is the process by which cells destroy themselves when they are damaged irrepairably by exposure to stressful stimuli or infectious agents, or when they no longer receive signals from specific survival factors [1] . The regulation of apoptosis is critical for many processes, including development, the defence against pathogens and the prevention of proliferation of transformed cells. Bcl-2 and related cytoplasmic proteins are key regulators of apoptosis [2] , and there has been much interest focussed upon their regulation over the past few years. One member of this family is BAD (Bcl-2\Bcl-X L -antagonist, causing cell death), a pro-apoptotic protein that binds to the anti-apoptotic proteins Bcl-2 and Bcl-X L [3] . This interaction is thought to neutralize the anti-apoptotic effects of Bcl-2\Bcl-X L and may represent one of the mechanisms by which BAD promotes apoptosis.
Zha et al. [4] were the first to report that treating lymphoid progenitor cells with interleukin-3 (IL-3) results in the phosphorylation of BAD. This causes BAD to interact with 14-3-3 proteins instead of Bcl-2 or Bcl-X L , resulting in the liberation of these anti-apoptotic proteins, which can then interact with Bax to inhibit apoptosis.
Two sites on BAD, Ser""# and Ser"$', were reported to be phosphorylated in i o [4] . Both sites lie in Arg-Xaa-Arg-Xaa-observations suggest that MAPKAP-K1 is the protein kinase that mediates the phosphorylation of Ser""# in i o by stimuli that activate the classical MAP kinase cascade.
cAMP-dependent protein kinase (PKA) was also reported to phosphorylate BAD at Ser""# and to be the major Ser""# kinase associated with a mitochondrial membrane fraction isolated from IL-3-stimulated cells. This appeared to be a particular form of PKA that was complexed to the PKA-anchoring protein (' AKAP ') 84 ; this protein targets PKA to the mitochondrial outer membrane [16] . These observations contrasted with the suggestion that the IL-3-induced phosphorylation of Ser""# was mediated by MAPKAP-K1. Moreover forskolin, a cAMPelevating agent, was reported to induce the phosphorylation of BAD at Ser""# in transfected 293 cells [14] .
Here we report that the major site on BAD phosphorylated by PKA in itro is not Ser""# or Ser"$', but Ser"&&. Moreover, Ser"&&, but not Ser""# or Ser"$', becomes phosphorylated when transfected 293 cells are stimulated by cAMP-elevating agents. The phosphorylation of Ser"&& triggers the dissociation of BAD from Bcl-2 and Bcl-X L and promotes its interaction with 14-3-3 proteins.
MATERIALS AND METHODS

Materials
Tissue-culture reagents, EGF and insulin-like growth factor-1 (IGF1) were purchased from Gibco BRL (Paisley, Renfrewshire, Scotland, U.K.) ; complete protease cocktail and sequencinggrade trypsin were from Boehringer (Lewes, East Sussex, U.K.), H89, PD 98059, Ro 318220, rapamycin and Zwittergent 3-16 were from Calbiochem (Nottingham, U.K.), forskolin, isobutylmethylxanthine (IBMX), wortmannin and PMA were from Sigma (Poole, Dorset, U.K.), Protein G-Sepharose was from Pharmacia (Milton Keynes, U.K.), pEBG-BAD plasmid expressing glutathione S-transferase (GST)-BAD was from New England Biolabs (NEB) (Hitchin, Herts., U.K.) and [γ-$#P]ATP was from Amersham (Little Chalfont, Bucks., U.K.). An antibody that recognizes 14-3-3γ (SC-73) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.).
Buffer solutions
Buffer A comprised 50 mM Tris\HCl, pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 % (w\v) Triton X-100, 1 mM sodium orthovanadate, 50 mM NaF, 5 mM sodium pyrophosphate, 0.27 M sucrose and 0.1 % β-mercaptoethanol. Cell-lysis buffer was Buffer A containing 2 µM microcystin-LR, 0.1 mM PMSF, 1 mM benzamidine. Buffer B comprised 50 mM Tris\HCl, pH 7.5, 1 mM EGTA, 0.1 % (v\v) β-mercaptoethanol and 0.05 % (w\v) Brij-35.
Expression of GST-BAD and His-Bcl-X L in Escherichia coli
A cDNA encoding full-length murine BAD was obtained by PCR from a mouse cDNA library and subcloned into a pGEX vector by Dr. Antonio Casamayor in this Unit. The Ser""# Ala\Ser"$' Ala double mutant was generated by using a PCRbased site-directed mutagenesis kit (Stratagene) and verified by DNA sequencing. The mutant constructs were transformed into BL21 DE3 (pLysS) E. coli and the GST fusion proteins purified on GSH-Sepharose. Each litre of bacterial culture yielded 1 mg of pure GST-BAD. A vector expressing the first 211 residues of Bcl-X L (lacking the C-terminal hydrophobic region) preceded by six histidine residues [17] was provided by Dr. Paul Clarke, Biomedical Research Centre, Ninewells Hospital, Dundee, Scotland, U.K. This was also expressed in E. coli and purified on Ni# + -nitrilotriacetate-agarose. Each litre of bacterial culture yielded 4 mg of pure His-Bcl-X L .
Isolation and assay of protein kinases
Protein kinases were provided by the members of this Unit indicated in parentheses : MAPKAP-K1b (RSK2) purified to near homogeneity from rabbit skeletal muscle [18] (Dr N. Morrice) ; the catalytic subunit of PKA purified to homogeneity from bovine cardiac muscle [19] (Dr C. Smythe) ; GST-mitogenand-stress-activated protein kinase-1 (MSK1) activated by ERK2 [20] (Dr A. Paterson) ; His-tagged PKBα activated by 3-phosphoinositide-dependent protein kinase-1 (PDK1 ; Dr C. Armstrong). One unit of protein kinase activity was that amount which catalysed the phosphorylation of 1 nmol of phosphate in 1 min in the standard assay at 30 mC. MAPKAP-K1, MSK1 and PKB were assayed using the peptide Gly-Arg-Pro-Arg-Thr-Ser-SerPhe-Ala-Glu-Gly (Crosstide, 30 µM) and PKA using the peptide Leu-Arg-Arg-Ala-Ser-Leu-Gly (Kemptide, 30 µM)
Tryptic digestion of phosphorylated BAD
GST-BAD (2 µM) purified from bacterial extracts was phosphorylated by incubation for 90 min at 30 mC with GST-MSK1, MAPKAP-K1, PKA or PKB, each at 10 units\ml in Buffer B plus 10 mM MgCl # and 0.1 mM [γ-$#P]ATP (5000 c.p.m.\pmol). After denaturation, electrophoresis on an SDS\10 % (w\v) polyacrylamide gel and Coomassie Blue staining, $#P-labelled full-length GST-BAD was excised from the gel and digested for 18 h with 1 µg of trypsin at 30 mC in 0.3 ml of digestion buffer (0.05 % Zwittergent 3-16 in 50 mM ammonium bicarbonate). The digest was centrifuged for 10 min at 13 000 g, extracted with a further 0.3 ml of digestion buffer and the supernatant, containing 90 % of the $#P radioactivity, chromatographed on a C ") column as described in the Figure legends.
Production of antibodies that recognize BAD
Polyclonal antibodies that recognize specific phosphorylation sites in murine BAD were raised against the following peptides (one-letter code) : RSRMSS*YPDRG (Ser""#), RGSRS*APPNL (Ser"$') and RELRRMS*DEFEGS (Ser"&&), where S* denotes a phosphorylated serine residue. These peptides were coupled with keyhole-limpet haemocyanin, and each injected into a different sheep at the Scottish Antibody Production Unit (Carluke, Ayrshire, U.K.). A second injection was made 6 weeks later. After a further 2 weeks, serum was withdrawn and affinity-purified by sequential chromatographies on phosphopeptide-CH-Sepharose and dephosphopeptide-CH-Sepharose. A further antibody that recognizes phosphorylated and dephosphorylated BAD was raised against the synthetic peptide WDRNLGRGSAPSQ, which corresponds to residues 162-174 of BAD. The antibodies used in the present study may be obtained from UBI (Lake Placid, NY, U.S.A.).
Cell culture
HEK-293 cells and monkey kidney COS1 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10 % (v\v) foetal-calf serum, at 37 mC, in an atmosphere of 5 % CO # .
Transient transfections, stimulation and cell lysis
Dishes (10 cm diameter) of HEK-293 cells were transfected with 10 µg of the pEBG-BAD plasmid (NEB) using a modified cAMP-dependent phosphorylation of BAD at Ser 155 calcium phosphate gel method [21] . After transfection (24 h), cells were serum-starved for 18 h, then stimulated for the times indicated with PMA, EGF, IGF1 or forskolin, with or without prior treatment for 1 h with PD 98059, U0126, Ro 318220, H89, wortmannin, LY 249002 or rapamycin, Each dish of cells was lysed in 1 ml of ice-cold lysis buffer, centrifuged at 4 mC for 10 min at 13 000 g, and the supernatants frozen immediately in liquid nitrogen and stored at k80 mC until use. Protein concentrations were determined [22] using BSA as standard.
Immunoblotting of BAD
Extracts of cells overexpressing GST-BAD were fractionated by electrophoresis on SDS\10 %-polyacrylamide gels and transferred to nitrocellulose membranes. Blots were blocked for 1 h at room temperature with 5 % (w\v) non-fat dried milk in 20 mM Tris\HCl (pH 7.5)\150 mM NaCl\0.1 % Tween 20, then incubated with primary antibody overnight at 4 mC, followed by incubation for 1 h with secondary antibody. Finally the blots were developed with enhanced chemiluminescence (ECL2) reagent (Amersham). All antibodies prepared in the present study were used at 0.1 µg\ml. Before use, all phosphospecific antibodies were preincubated with the dephosphorylated form of the relevant phosphopeptide immunogen (10-50 µg\ml). This was done to neutralize any antibodies present that might recognize the dephosphorylated form of BAD.
Bcl-X L binding assay
GST-BAD (1 µg) was phosphorylated in itro by incubation for 1 h at 30 mC with or without MSK1, MAPKAP-K1, PKA or PKB (each at 10 units\ml) in Buffer B containing 10 mM MgCl # and 0.1 mM [γ-$#P]ATP (500 c.p.m.\pmol). The solutions (25 µl) were further incubated for 1 h at 4 mC with 5 µg His-Bcl-X L in 50 µl of lysis buffer, and the BAD complexed to Bcl-X L was captured on Ni# + -nitrilotriacetate-agarose beads. After centrifugation for 5 min at 13 000 g, the supernatants (S) were set aside and the pellets (P) washed five times with lysis buffer. The supernatants and final pellets were denatured in SDS, and the solubilized proteins electrophoresed on SDS\10 %-polyacrylamide gels and transferred to nitrocellulose. The membranes were autoradiographed and further analysed by immunoblotting with the antibody that recognizes phosphorylated and dephosphorylated BAD equally well.
14-3-3 overlay
GST-BAD was phosphorylated for 1 h and 30 mC in itro by incubation with 10 units\ml of GST-MSK1, MAPKAP-K1, PKA or PKB, in buffer B containing 10 mM MgCl # and 0.1 mM unlabelled ATP. Samples were denatured in SDS, electrophoresed on a SDS\10 %-polyacrylamide gel and transferred to nitrocellulose. 14-3-3 overlay assay was performed using the mixed BMH1 and BMH2 isoforms of Saccharomyces cere isiae 14-3-3 proteins each labelled with digoxygenin [23] .
RESULTS
Phosphorylation of BAD in vitro by different protein kinases
MAPKAP-K1 is not the only protein kinase that is activated by the MAP kinase family members ERK1 and ERK2. In particular, MSK1 and the closely related MSK2 are also physiological substrates for ERK1\ERK2 [20] and are therefore candidates to
Figure 1 Separation of the tryptic phosphopeptides in BAD after phosphorylation in vitro by PKB, MSK1, MAPKAP-K1 and PKA
The 32 P-labelled peptides obtained by tryptic digestion of BAD phosphorylated by the protein kinases indicated (see the Materials and methods section) were chromatographed on a Vydac 218TP54 C 18 column (Separations Group, Hesperia, CA, U.S.A.) equilibrated with 0.1 % trifluoroacetic acid. The column was developed with a linear acetonitrile gradient in 0.1 % trifluoroacetic acid (dotted lines). The flow rate was 0.8 ml/min, and fractions, 0.4 ml each, were collected. All 240 fractions were counted for 32 P radioactivity (continuous lines). Typically 90 % of the 32 P radioactivity applied to the column was recovered in the eluted fractions. The four major 32 P-labelled peptides eluted at fractions 116 (termed T1b), 128 (termed T2), 130 (termed T1a) and 158 (termed T3) are indicated. No 32 P radioactivity was detected in fractions 1-100 and 181-240 (results not shown). Similar results were obtained in three separate experiments for (B), (C) and (F) and two experiments for (A), (D) and (E).
mediate the phosphorylation of BAD at Ser""#. For this reason, we compared the phosphorylation of BAD by MAPKAP-K1 and MSK1 (Figure 1 ).
MAPKAP-K1 (1 unit\ml) or MSK1 (10 units\ml) both phosphorylated BAD to about 1 mol\mol of protein after 90 min. Digestion with trypsin, followed by chromatography on a C ") column revealed that MAPKAP-K1 had phosphorylated BAD at one major tryptic phosphopeptide termed T3 ( Figure  1A ), which was identified by MS (Table 1) and Edman sequencing (results not shown), as the peptide comprising residues 110-130 phosphorylated at Ser""#, as expected. In contrast, MSK1 phosphorylated a distinct tryptic peptide, T1a ( Figure 1C ), which was eluted at almost the same acetonitrile concentration as the single tryptic peptide phosphorylated by PKB (10 units\ml), termed phosphopeptide T2 ( Figure 1D ). Peptide T2 was identified by MS (Table 1) and Edman sequencing (results not shown) as the peptide comprising residues 134-146 of BAD, phosphorylated at Ser"$' as expected. Surprisingly, however, peptide T1a was found not to be identical with peptide T2, but to comprise residues 153-163 of BAD (Table 1 ) phosphorylated at Ser"&& ( Figure 2A ).
Table 1 Identification of tryptic phosphopeptides isolated from BAD phosphorylated with different protein kinases
The phosphopeptides from Figure 1 were analysed on a Perseptive Biosystems (Framingham, MA, U.S.A.) Elite STR matrix-assisted laser-desorption-ionization-time-of-flight (' MALDI-TOF ') mass spectrometer in the linear and reflector mode, using 10 mg/ml α-cyanocinnamic acid as the matrix. The asterisk (*) indicates a methionine sulphone derivative. Interestingly, the minor tryptic phosphopeptide phosphorylated by low concentrations of MAPKAP-K1 (1 unit\ml, Figure  1A ) co-migrated with peptide T1a and also comprised residues 153-163 (Table 1 ) phosphorylated at Ser"&& (results not shown). When the concentration of MAPKAP-K1 was increased to 10 units\ml, the phosphorylation of BAD approached 2 mol of phosphate\mol of protein, and peptide T1a was now phosphorylated at Ser"&& to a much high stoichiometry (Figures 1B, 2B and Table 1 ). The molecular mass of the minor tryptic phosphopeptide T1b ( Figures 1A, 1B and 1C ) corresponded to that of T1a in which the methionine at residue 154 was partially oxidized to methionine sulphone (Table 1) . Peptide T1a is likely to correspond to the unoxidized peptide, which becomes oxidized after its elution from the C ") column and before its analysis by MS.
The amino acid sequence surrounding Ser"&& (Arg-Arg-MetSer) is the preferred consensus sequence for phosphorylation by PKA (reviewed in [24] ), which prompted us to re-examine the phosphorylation of BAD by this protein kinase. At 1 unit\ml, PKA phosphorylated BAD at one major and one minor tryptic phosphopeptide, co-eluting with peptides T1a and T1b respectively ( Figure 1E ). MS (Table 1) and Edman sequencing ( Figure  2C ) confirmed that both peptides comprised residues 153-163 phosphorylated at Ser"&&. At 1 unit\ml PKA there was no detectable phosphorylation of Ser""# or Ser"$' after 90 min phosphorylation. However, only a low level of phosphorylation of peptide T2 (containing Ser"$') and trace phosphorylation of peptide T3 (containing Ser""#) was observed when the concentration of PKA was increased to 10 units\ml ( Figure 1F ). Further analysis of the traces of peptide T3 revealed that it was a mixture of two phosphopeptides, one phosphorylated at Ser""" and the other at Ser""# (results not shown). The results presented in Figures 1(E) and 1(F) were obtained using PKA purified from bovine heart in our Unit. However, identical results were obtained with PKA from porcine heart and bovine heart purchased from Sigma (results not shown), the source of the PKA used previously by others [16] . The phosphorylation of BAD by all preparations of PKA was prevented by inclusion of the 
Figure 2 Identification of the phosphorylation sites in peptide T1a
Phosphopeptides T1a from Figures 1(B) , 1(C) and 1(F) were sequenced by Edman degradation using an Applied Biosystems 492A protein sequencer. 32 P radioactivity released after each cycle was measured in a separate experiment by solid-phase Edman degradation of the peptides coupled to a Sequelon-AA membrane (Milligen, Bedford, MA, U.S.A.) as described previously [34] .
specific peptide inhibitor of PKA (PKI) in the assays (results not shown).
Consistent with the results presented in Figures 1 and 2 , the stoichiometry of phosphorylation of BAD by MSK1 (10 units\ml) was not decreased, and the phosphorylation of BAD by PKA (10 units\ml) only decreased from 2 mol\mol to 1 mol\mol when Ser""# and Ser"$' were both mutated to Ala. In contrast, phosphorylation by PKB was abolished, as expected (results not shown).
Phosphorylation of BAD at Ser 155 is stimulated by forskolin, but not by PMA, EGF or IGF1 in 293 cells
In order to study the site-specific phosphorylation of BAD in response to different agonists, we raised three different antibodies that recognize this protein only when it is phosphorylated at one of the three known sites. The specificity of these antibodies is cAMP-dependent phosphorylation of BAD at Ser demonstrated in Figure 3 . The antibody raised against a phosphopeptide corresponding to the sequence surrounding Ser""# recognized BAD only after phosphorylation by MAPKAP-K1, but not after phosphorylation at Ser"$' by PKB or at Ser"&& by MSK1 ( Figure 3A ). The recognition of Ser""# by this antibody was abolished when it was incubated with the phosphopeptide immunogen used to raise it, but not when it was incubated with the phosphopeptides used to raise the anti-Ser"&& antibody ( Figure 3B ) or the anti-Ser"$' antibody (results not shown). The specificities of the antibodies raised against phosphopeptides corresponding to the sequences surrounding Ser"$' and Ser"&& were established in analogous experiments (Figure 3) . These antibodies were then used to examine the site-specific phosphorylation of GST-BAD in 293 cells. As indicated below, each antibody recognized a single 50 kDa protein in the transfected cells, corresponding to GST-BAD that was absent in control cells transfected with an empty vector (results not shown).
In unstimulated 293 cells transfected with GST-BAD, the level of phosphorylation of Ser"&& was low, but increased strikingly in response to the adenylate cyclase activator forskolin and the cAMP phosphodiesterase inhibitor IBMX (Figure 4A ), reaching a plateau at 5-15 min (results not shown). In contrast, forskolin (with or without IBMX) did not stimulate the phosphorylation of BAD at Ser""# or Ser"$' up to 30 min using our phosphospecific antibodies (Figure 4) .
Ro 318220 is a bisindoylmaleimide, originally developed as an inhibitor of protein kinase C (PKC), but which inhibits MAPKAP-K1 and MSK1 with similar potency to PKC in itro [20, 25] . In contrast, PKA and PKB are only inhibited by Ro 318220 at far higher concentrations [25] . Ro 318220 (5 µM) did not affect the forskolin\IBMX-induced phosphorylation of Ser"&& ( Figure 4B ), a concentration that blocked PMA-or EGF-induced 
Phosphorylation of BAD at Ser 112 is stimulated by EGF and PMA
The classical MAP kinase cascade was maximally activated after 5 min (EGF) or 15 min (PMA), as judged by the activation of MAPKAP-K1 ( Figures 5A and 5B ). EGF and PMA both stimulated the phosphorylation of BAD at Ser""# at a rate consistent with the rate of activation of MAPKAP-K1 ( Figures  5A and 5B). EGF and PMA did not stimulate the phosphorylation of BAD at Ser"$' or Ser"&& up to 30 min ( Figure 5 ).
Figure 5 Phosphorylation of BAD at Ser 112 by EGF and PMA correlates with the activation of MAPKAP-K1
293 cells transfected with a plasmid encoding GST-BAD were stimulated for the times indicated with 100 ng/ml EGF (A) or 400 ng/ml PMA (' TPA ' ; (B). MAPKAP-K1 was immunoprecipitated from lysates [35] and assayed as described in the Materials and methods section. The activities are presented as meanspS.E.M. for three separate experiments. Aliquots of the cell lysate (25 µg of protein) were then denatured in SDS, electrophoresed on SDS/10 %-polyacrylamide gels and, after transfer to nitrocellulose, immunoblotted with the four antibodies used in Figure 3 .
The phosphorylation of Ser""# induced by EGF ( Figure 6A ) or PMA ( Figure 6B ) was prevented by PD 98059 or by U0126 (another specific inhibitor of the MAP kinase cascade [27] ), but not by wortmannin or rapamycin. Ro 318220 completely prevented the PMA-stimulated phosphorylation of Ser""# at 1 µM ( Figure 6B ). EGF-stimulated Ser""# phosphorylation was unaffected at this concentration of Ro 318220, but strongly suppressed at 5 µM Ro 318220 ( Figure 6A ). H89 (10 µM) had no effect on the EGF-induced phosphorylation of Ser""# (results not shown), consistent with H89 being a much weaker inhibitor of MAPKAP-K1 than PKA or MSK1 ([26] ; S. Davies, H. Reddy and P. Cohen, unpublished work).
Phosphorylation of BAD at Ser 136 in transfected 293 cells is not affected by IGF1 or by inhibitors of PI3K
IGF1 induced a strong activation of PKB in 293 cells that was maximal after 5 min, sustained for at least 60 min and prevented by the PI3K inhibitor wortmannin [28] (Figure 7 ). IGF1 did not stimulate any increase in the phosphorylation of BAD at Ser""#, Ser"$' or Ser"&&, and nor was the basal level of phosphorylation of any of these sites in unstimulated cells affected by incubation for 1 h with 100 nM wortmannin (Figure 7 ) or overnight with 100 µM LY 294002 (results not shown), another inhibitor of PI3K.
Effect of site-specific phosphorylation on the interaction of BAD with Bcl-X L and 14-3-3 proteins
BAD was phosphorylated in itro by incubation with Mg[γ-$#P]-ATP and concentrations of MAPKAP-K1, MSK1, PKA and PKB that produced near-stoichiometric phosphorylation of particular sites. A fivefold excess of His-tagged Bcl-X L was added and the proportion of BAD complexed to Bcl-X L was determined after pulling down the Bcl-X L on Ni# + -nitrilotriacetate-agarose ( Figure 8A ). When BAD was not phosphorylated, it was entirely bound to Bcl-X L. In contrast, no $#P-labelled BAD was bound to Bcl-X L after phosphorylation by MAPKAP-K1, PKA or MSK1, as judged by immunoblotting or autoradiography. However, 50 % of the $#P-labelled BAD was still bound to Bcl-X L after phosphorylation to 1 mol\mol with PKB ( Figure 8A) .
In a separate experiment, BAD was phosphorylated as described above, but with unlabelled ATP. The BAD was electrophoresed on a polyacrylamide gel and, after transfer to nitrocellulose, the membranes were blotted with digoxygeninlabelled 14-3-3 proteins. An interaction with 14-3-3 proteins was detected after phosphorylation of BAD by MAPKAP-K1, MSK1, PKA or PKB. No 14-3-3 binding was detected before phosphorylation ( Figure 8B ). The interaction with 14-3-3 proteins was prevented by preincubating the 14-3-3 probe with a synthetic phosphopeptide corresponding to residues 149-161 of BAD phosphorylated at Ser"&& (results not shown).
In order to examine whether agonist-stimulated phosphorylation of GST-BAD in 293 cells would induce its interaction with endogenous 14-3-3 proteins, we purified the GST-BAD from these cells and, after electrophoresis, tested for the presence of 14-3-3γ with a specific antibody. These experiments revealed a low level of 14-3-3γ associated with GST-BAD from control cells, which increased considerably when the cells were stimulated with EGF, PMA or forskolin ( Figure 8C ). The amount of 14-3-3γ was not, however, increased by stimulation with IGF1, consistent with the failure of this agonist to increase the phosphorylation of Ser"$' or any other site (Figure 7) .
Comparison of our Ser
112
-phosphospecific antibody with that produced by NEB Our finding that Ser"&& is the only site that becomes phosphorylated in 293 cells exposed to cAMP-elevating agents ( Figure  4 ) was in conflict with the results of other investigators who reported that forskolin induced the phosphorylation of Ser""# in 293 cells transfected with BAD [14] . Since the only obvious
Figure 6 Effects of different protein kinase inhibitors on the EGF-and PMA-induced phosphorylation of BAD at Ser 112 in 293 cells
293 cells transfected with a plasmid encoding GST-BAD were stimulated for 5 min with 100 ng/ml EGF (A) or for 15 min with 400 ng/ml PMA (' TPA ' ; B). Prior stimulation with agonist, the cells were pretreated for 1 h with PD 98059, U0126, Ro 318220, wortmannin or rapamycin at the concentrations indicated. Cell lysates (25 µg of protein) were denatured in SDS, electrophoresed on SDS/10 %-polyacrylamide gels and, after transfer to nitrocellulose, immunoblotted with the antibody specific for BAD phosphorylated at Ser 112 (' Ser112 '). The membranes were then stripped and re-probed with the antibody that recognizes phosphorylated and dephosphoryated BAD equally well (' BAD ').
difference between these studies and our own was the source of the phosphospecific antibody, we compared the specificity of the anti-Ser""# antibody made by NEB with our own antibody. These studies revealed that the NEB antibody recognized BAD phosphorylated by PKB at Ser"$' and BAD phosphorylated by MSK1 at Ser"&&, albeit more weakly than BAD phosphorylated by MAPKAP-K1 at both Ser""# and Ser"&& ( Figure 9A ). In contrast, our antibody only recognized Ser""# under the same conditions (Figure 3) .
In order to see whether the lack of specificity of the NEB antibody was the cause of the discrepancy, we stimulated BADtransfected 293 cells with forskolin or PMA, and then tested for BAD phosphorylation at Ser""#. As expected, our anti-Ser""# antibody recognized BAD only when the cells were stimulated with PMA and not when they were stimulated with forskolin. In contrast, the anti-Ser""# antibody from NEB recognized BAD after the cells were stimulated with PMA or forskolin ( Figure  9B ). The weaker effect of forskolin on ' Ser""# phosphorylation ' is similar to that reported by Tan et al. [14] and is consistent with the weak recognition of the Ser"&& site by the NEB ' anti-Ser""# ' antibody.
Figure 7 Phosphorylation of BAD at Ser 136 does not correlate with PKB activation
293 cells transfected with a plasmid encoding GST-BAD were stimulated with 100 ng/ml IGF1 for 5 or 20 min. Prior to stimulation with agonist, the cells were pretreated for 1 h with or without 100 nM wortmannin. PKBγ was immunoprecipitated from 50 µg of cell lysate [36] and assayed as described in the Materials and methods section. The activities are presented as meanspS.E.M. for three separate experiments. Cell lysates (25 µg of protein) were denatured in SDS, electrophoresed on SDS/10 %-polyacrylamide gels and, after transfer to nitrocellulose, immunoblotted with the four antibodies used in Figure 3 .
Figure 8 Effect of site-specific phosphorylation on the interaction of BAD with Bcl-X L and 14-3-3 proteins
(A) Interaction of BAD with Bcl-X L . This was carried out as described in the Materials and methods section. The membranes were autoradiographed (lower panels) and further analysed by immunoblotting with the antibody that recognizes phosphorylated and dephosphorylated BAD equally well (upper panels). (B) 14-3-3 overlay. GST-BAD was phosphorylated and processed as in (A), but with unlabelled ATP. The 14-3-3 overlays (upper panel) were performed as described in the Materials and methods section using the BMH1 and BMH2 isoforms of S. cerevisiae. The membranes were then stripped and re-probed with the antibody that recognizes phosphorylated and dephosphoryated BAD equally well (lower panel). (C) Agonist-induced interaction of GST-BAD with endogenous 14-3-3γ. 293 cells were transfected with GST-BAD, then stimulated with EGF (5 min), PMA (' TPA' ; 15 min) or forskolin (30 min) or IGF1 (10 min) as in Figures 4, 5 and 7 . After cell lysis, 20 µg of lysate was incubated for 1 h with 10 µl of packed GSH-agarose. After brief centrifugation, the supernatant was discarded and the beads washed four times with 1 ml of Buffer A containing 125 mM NaCl. Finally, the pellet was denatured in SDS, the solubilized proteins electrophoresed, transferred to nitrocellulose and analysed by immunoblotting with an antibody that recognises 14-3-3γ (upper panel). The membrane was stripped and re-probed with the same anti-BAD antibody as in (B) (lower panel). 
Phosphorylation of endogenous BAD in COS1 cells
The analysis of the phosphorylation of BAD in 293 cells described so far was carried out using cells in which GST-BAD was overexpressed. It was therefore important to extend the work to examine whether the much lower levels of BAD present endogenously in mammalian cells were phosphorylated at Ser"&& in response to cAMP elevation. After testing many cell lines we found that the level of BAD in COS1 cells was just sufficient to carry out this experiment. These studies showed that forskolin stimulates the phosphorylation of endogenous BAD at Ser"&& ( Figure 10A ), confirming the results obtained in transfected 293 cells (Figure 4) .
DISCUSSION
In the present paper we identify Ser"&& as a novel phosphorylation site in BAD. This residue lies in an optimal consensus sequence for phosphorylation by PKA (Arg-Arg-Xaa-Ser) and is phosphorylated by this protein kinase at a far higher rate in itro than any other site. Ser""# and Ser"$' were only trace-phosphorylated, even after prolonged incubation with high concentrations of PKA ( Figure 1F ). Consistent with these findings, Ser"&& was the only one of these three residues that became phosphorylated in transfected 293 cells ( Figure 4 ) stimulated with the cAMP-elevating agents forskolin and IBMX. Moreover, the endogenous BAD in COS1 cells was phosphorylated at this site in response to the same agonists ( Figure 10 ). Ser"&& is also phosphorylated in itro by MSK1 ( Figure 1C ) and, at a low rate, by MAPKAP-K1 ( Figures 1A and 1B) . However, neither of these protein kinases appear to be rate-limiting for the phosphorylation of Ser"&& in 293 cells, because Ser"&& phosphorylation was not induced by stimulation with agonists that activate the classical MAP kinase cascade (EGF, PMA) and hence activate MSK1 [20] and MAPKAP-K1 ( Figure 5) . Similarly, exposure to UV-C radiation or to the protein-synthesis inhibitor anisomycin, under conditions that strongly activate MSK1 in 293 cells via the SAPK2\p38 pathway [20] , did not induce any phosphorylation of BAD at Ser"&& (results not shown).
The specific phosphorylation of BAD at Ser"&& by MSK1 in itro ( Figure 1C ) triggered its dissociation from Bcl-X L even more effectively than the specific phosphorylation of BAD at Ser"$' by PKB ( Figure 8A ) and induced a similar interaction with 14-3-3 proteins ( Figure 8B) . Moreover, the forskolin-induced phosphorylation of BAD at Ser"&& promoted its interaction with the endogenous 14-3-3γ present in 293 cells (Figure 8C ), in a similar manner to the PMA or EGF-induced phosphorylation of Ser""# ( Figure 8C ). Since forskolin stimulates the phosphorylation of Ser"&&, but not Ser""# or Ser"$' (Figure 4) , this establishes that BAD can interact with 14-3-3 proteins when phosphorylated at Ser"&&. However, unlike Ser""# and Ser"$', Ser"&& does not lie in the sequence Arg-Xaa-Xaa-Ser(P)-Xaa-Pro, which is the canonical consensus for binding to 14-3-3 proteins. However, there are precedents for 14-3-3 proteins binding to phosphorylated sequences lacking proline at the j2 position. For example, the 14-3-3 binding sequence in protein tyrosine phosphatase H1, lies in the sequence Arg-Ser-Leu-Ser(P)-Val-Glu [29] , which is similar to that surrounding Ser"&& (Arg-Arg-Met-Ser(P)-Asp-Glu). The phosphopeptide comprising residues 149-161 prevented the interaction of Ser"&&-phosphorylated BAD with 14-3-3 proteins (results not shown), demonstrating that this sequence does indeed bind to 14-3-3 proteins. In summary, our results show that the phosphorylation of BAD at Ser"&& triggers the dissociation of BAD from Bcl-X L and its interaction with 14-3-3 proteins. This may contribute to the anti-apoptotic effects of cAMP-elevating
Scheme 1 BAD is phosphorylated at different sites in response to agonists that activate distinct signal-transduction pathways
The sites of action of the kinase inhibitors used in the present paper are indicated. PK ? indicates that phosphorylation of BAD at Ser 136 in 293 cells is catalysed by a protein kinase that has not yet been identified. ' TPA ' is PMA. agents, which have been well documented in several systems, including cerebellar granule neurons [30] , developing retina [31] and neutrophils [32] .
Our results do not agree with those of Harada et al. [16] , who reported that Ser""# was the major residue phosphorylated by the purified catalytic subunit of PKA, purchased from Sigma, and a form of PKA associated with a mitochondrial fraction isolated from IL-3-stimulated FL5.12 cells. However, in the studies by Harada et al., Ser""# was not identified directly, and phosphorylation was only inferred from the observation that phosphorylation was greatly reduced if Ser""# was mutated to Ala. The discrepancy between their results and ours is not explained by the source of the PKA, since we found that Ser"&& was the major site phosphorylated with three different catalytic subunit preparations, including PKA from Sigma (see the Results section). These observations point to the importance of identifying phosphorylation sites directly by isolating and sequencing the relevant phosphopeptides, and highlight the potential dangers inherent in indirect methods that are based on decreased phosphorylation of mutant proteins.
Our results also disagree with those of Tan et al. [14] , who reported that the phosphorylation of Ser""# in BAD-transfected 293 cells was stimulated by the cAMP-elevating agent forskolin. In the present study, no phosphorylation of Ser""# could be detected after stimulation by forskolin (Figure 4 ). This discrepancy appears to be explained by the anti-Ser""# antibody used by Tan et al. [14] , which, in contrast with our antibody (Figure 3 ), recognized BAD phosphorylated at Ser"$' and Ser"&&, as well as BAD phosphorylated at Ser""# ( Figure 9A ). Thus, in their studies, the forskolin-induced phosphorylation of ' Ser112 ' was really measuring the phosphorylation of Ser"&& ( Figure 9B ). Although phosphospecific antibodies can be extremely valuable, our findings illustrate the potential hazard of relying exclusively on such antibodies the specificity of which has not been established rigorously. It is also essential to establish that a phosphospecific antibody is neutralized by the phosphorylated peptide immunogen and not by the corresponding dephosphopeptide. This is not possible with phosphospecific antibodies marketed by NEB, since they do not sell the phosphopeptide antigen that they use to raise a particular antibody and will not even reveal its identity.
In the present study we showed that the phosphorylation of BAD at Ser""# was stimulated by exposure to agonists that activate the classical MAP kinase cascade (EGF, PMA ; see Figure 5 ), and similar results were obtained by other investigators while our studies were in progress [14, 15] . The agonist-induced phosphorylation of Ser""# was prevented by two structurally distinct inhibitors of the MAP kinase cascade, namely PD 98059 ( Figure 6 ) [15] and U0126 ( Figure 6 ). The failure of Tan et al. [14] to observe a strong inhibition of PMA-induced phosphorylation of Ser""#, may be explained by the lower concentration of PD 98059 used in their experiments. The difficulty of completely suppressing activation of the MAP kinase cascade by agonists that are particularly strong activators of this pathway has been discussed previously [12] . The phosphorylation of endogenous BAD at Ser""# via the classical MAP kinase cascade has also been demonstrated in IL-3-dependent MC9 cells [11] and BDNFstimulated cerebellar granule neurons [13] .
MAPKAP-K1 is the only identified protein kinase in the classical MAP kinase cascade that phosphorylates BAD at Ser""#
